Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and ISRT for Early Stage Relapsed or Refractory Hodgkin Lymphoma
NCT03179917Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2017
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Hodgkin lymphoma (HL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Complete Response Rate Following Pembrolizumab-ISRT at 2 years, Overall Response Rate Following Single-agent Pembrolizumab at 2 years and 2 more. Started Jun 2017; status: active, not recruiting.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03179917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179917.